Vivaldi Capital Management LLC Buys Shares of 1,306 Amgen, Inc. (AMGN)
Vivaldi Capital Management LLC bought a new position in Amgen, Inc. (NASDAQ:AMGN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,306 shares of the medical research company’s stock, valued at approximately $254,000.
Several other institutional investors and hedge funds have also recently modified their holdings of AMGN. Ruggie Capital Group increased its holdings in Amgen by 297.1% in the 4th quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 101 shares in the last quarter. Arlington Partners LLC increased its holdings in Amgen by 86.7% in the 4th quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 65 shares in the last quarter. Massey Quick Simon & CO. LLC increased its holdings in Amgen by 710.5% in the 4th quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 135 shares in the last quarter. Next Capital Management LLC acquired a new stake in Amgen in the 4th quarter valued at $33,000. Finally, Essex Investment Management Co. LLC acquired a new stake in Amgen in the 4th quarter valued at $39,000. 79.18% of the stock is currently owned by institutional investors and hedge funds.
Shares of Amgen stock opened at $193.89 on Thursday. The company has a debt-to-equity ratio of 2.36, a current ratio of 2.79 and a quick ratio of 2.57. The stock has a market cap of $118.87 billion, a PE ratio of 13.46, a price-to-earnings-growth ratio of 2.36 and a beta of 1.21. Amgen, Inc. has a 1-year low of $165.22 and a 1-year high of $210.19.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $5.80 annualized dividend and a dividend yield of 2.99%. Amgen’s payout ratio is 40.28%.
In other news, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction dated Thursday, February 7th. The shares were sold at an average price of $190.00, for a total transaction of $380,000.00. Following the transaction, the director now owns 14,988 shares of the company’s stock, valued at $2,847,720. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 6,000 shares of company stock worth $1,144,120 in the last ninety days. Corporate insiders own 0.27% of the company’s stock.
Several brokerages recently issued reports on AMGN. Oppenheimer set a $224.00 price target on Amgen and gave the company a “buy” rating in a report on Sunday, January 27th. Morgan Stanley lowered their price target on Amgen from $213.00 to $212.00 and set an “overweight” rating for the company in a report on Wednesday, December 19th. Mizuho reiterated a “buy” rating and issued a $211.00 price target on shares of Amgen in a report on Tuesday, February 26th. BidaskClub downgraded Amgen from a “buy” rating to a “hold” rating in a report on Wednesday, February 20th. Finally, Citigroup raised their target price on Amgen from $204.00 to $210.00 and gave the company a “neutral” rating in a research note on Friday, January 4th. Eleven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $209.00.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Article: Call Option Volume
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.